Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

Evanthia Galanis, Lynn C. Hartmann, William A. Cliby, Harry J. Long, Prema P. Peethambaram, Brigitte A. Barrette, Judith S. Kaur, Paul J. Haluska, Ileana Aderca, Paula J. Zman, Jeff A. Sloan, Gary Keeney, Pamela J. Atherton, Karl C. Podratz, Sean C. Dowdy, C. Robert Stanhope, Timothy O. Wilson, Mark J. Federspiel, Kah Whye Peng, Stephen J. Russell

Research output: Contribution to journalArticle

178 Scopus citations

Abstract

Edmonston vaccine strains of measles virus (MV) have shown significant antitumor activity in preclinical models of ovarian cancer. We engineered MV to express the marker peptide carcinoembryonic antigen (MVCEA virus) to also permit real-time monitoring of viral gene expression in tumors in the clinical setting. Patients with Taxol and platinum-refractory recurrent ovarian cancer and normal CEA levels were eligible for this phase I trial. Twenty-one patients were treated with MV-CEA i.p. every 4 weeks for up to 6 cycles at seven different dose levels (103-109 TCID50). We observed no dose-limiting toxicity, treatment-induced immunosuppression, development of anti-CEA antibodies, increase in anti-MV antibody titers, or virus shedding in urine or saliva. Dose-dependent CEA elevation in peritoneal fluid and serum was observed. Immunohistochemical analysis of patient tumor specimens revealed overexpression of measles receptor CD46 in 13 of 15 patients. Best objective response was dose-dependent disease stabilization in 14 of 21 patients with a median duration of 92.5 days (range, 54-277 days). Five patients had significant decreases in CA-125 levels. Median survival of patients on study was 12.15 months (range, 1.3-38.4 months), comparing favorably to an expected median survival of 6 months in this patient population. Our findings indicate that i.p. administration of MV-CEA is well tolerated and results in dose-dependent biological activity in a cohort of heavily pretreated recurrent ovarian cancer patients.

Original languageEnglish (US)
Pages (from-to)875-882
Number of pages8
JournalCancer research
Volume70
Issue number3
DOIs
StatePublished - Feb 1 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer'. Together they form a unique fingerprint.

  • Cite this